CRIS

Business Context and Reporting Period

Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: Curis is a therapeutic drug discovery and development company focused on regulatory signaling pathways controlling tissue repair and regeneration. The company operates primarily through strategic alliances and collaborations rather than direct commercialization.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 183% to $984,300 for the six months ended June 30, 2003, compared to $348,235 in the prior year. This increase was driven primarily by collaboration revenues from ES Cell and the commencement of revenue recognition from a $5,000,000 upfront license fee from Genentech.
• Significant Reduction in Net Loss: The net loss decreased dramatically from $88.8 million in the prior year to $9.2 million. The prior year's loss was heavily impacted by a one-time non-cash goodwill impairment charge of approximately $64.1 million and realignment expenses of $3.5 million, neither of which occurred in the current period.
• Operating Expense Reduction: Research and development expenses decreased 26% to $6.5 million, and general and administrative expenses decreased 42% to $3.0 million, largely due to staff reductions in late 2002 and reduced legal fees.
• Collaboration Terminations: The company terminated its joint venture with Elan Corporation (Curis Newco) in May 2003, consolidating the entity and eliminating future equity losses from the joint venture. The collaboration with Aegera Therapeutics was also terminated.

Guidance, Outlook, and Risks

• New Strategic Alliance: In June 2003, Curis entered a collaboration with Genentech for cancer therapy applications involving Hedgehog signaling pathway antagonists. The deal includes a $5,000,000 upfront payment (received July 2003), license fees, milestones, and royalties. Curis also sold $3,500,000 of common stock to Genentech as partial consideration.
• Liquidity Outlook: Management states that existing capital resources, combined with the Genentech upfront payment, are sufficient to fund operations into the third quarter of 2005.
• Future Funding Needs: The company expects to incur substantial additional losses and will require significant capital for R&D. Future funding may be sought through equity or debt financings, which could result in dilution.
• Risks: Key risks include the failure to achieve profitability, dependence on collaborative partners for development and commercialization, potential inability to secure additional financing, and the uncertainty of clinical trial outcomes and regulatory approvals.

Investor Verification Checklist

• Genentech Deal Terms: Verify the specific milestones and performance obligations required to recognize the $5,000,000 upfront payment and future royalties.
• Cash Burn Rate: Confirm the sustainability of the "third quarter of 2005" runway given the company's continued operating losses and lack of product revenue.
• Debt Covenants: Review the terms of the convertible notes payable to Elan Pharma International and Becton Dickinson, including conversion rates and maturity dates.
• Deferred Revenue: Assess the timing of revenue recognition for the $16.7 million in long-term deferred revenue, primarily related to the Micromet and Genentech agreements.
• Stock Dilution: Monitor the impact of the recent stock issuances to Genentech and Elan on existing shareholder equity.